Artificial narrow intelligence models, trained for specific intended purposes, have gained approval and recommendation for cancer treatment. Generalist medicial artificial intelligence (GMAI) models are now being developed for cancer treatment. Policy makers have a stark choice: radically adapt frameworks, block generalist approaches or force them onto narrower tracks.